A test to predict the future and act before the worst happens…Improve the quality of life for diabetics while reducing health care costs for the Government of Quebec…This is the achievement of the company at Montrealer Optithera and its team of CRCHUM researchers. Its unique test will soon be marketed globally for predicting major complications of type 2 diabetes.
After 12 years of research and $22 million, Drrupee Pavel Hammett and Johann Tremblay have finally succeeded in developing their own genetic test for type 2 diabetes.
You should know that diabetes increases the risk of heart, kidney, nervous system and eye diseases, which have serious consequences for patients’ quality of life.
“When we started, we didn’t even have the tools to do what we do today,” D explains on the phone.s Pavel Hammett, founding president of OPTITHERA and researcher at CRCHUM and professor of medicine at the University of Montreal.
colleague dReturn Johan Tremblay, co-founder of OPTITHERA, was looking for a way to use genetics to detect complications of diabetes after a global study showed that intensive treatments reduce patient mortality.
I’ve always been concerned that we don’t have the power to decide who should receive intensive treatment and who should not. with my colleague dReturn Tremblay, we wondered if we could detect risks of complications before their arrival and double treatment in high-risk patients before their first symptoms appeared.
considered ds Pavel Hammett
Currently, patients are treated when they develop symptoms.
Thanks to genetic information and artificial intelligence, which were not available at the beginning of their research and which allows processing hundreds of millions of data for each patient, the two researchers achieved their goal.
Their testing can determine if a patient is at low, normal, medium or high risk. “For those at low, normal, and moderate risk, we will tell the doctor to continue applying what he is already doing, but for those at high risk, we suggest ramping up treatment.”
“Because it has been shown that intensive treatment of patients with diabetes who are at risk of developing kidney disease, for example, delays dialysis by five years,” continues Dr.s hovered. There are medications that are given after a problem has occurred. ”
Save costs and improve health
In order to make the test free, OPTITHERA will try to prove to the Quebec government that it saves money in healthcare. considered ds Hamet cites the example of kidney failure, a complication of diabetes. People on dialysis cost the health care system $100,000 a year. Delaying dialysis by five years saves $500,000 and improves patients’ quality of life. ”
Test to do at home
The test will be available in Quebec and Canada in about six months, and then in the United States and Europe. considered drupee Pavel and Tremblay hope it will be covered by the government. In the meantime, patients with type 2 diabetes will be able to order it themselves on the OPTITHERA website, with or without an order from their physician, at a cost of approximately $400.
Diabetics receive the box at home, do a saliva test, and then send the sample to a laboratory connected to the company. The results are then sent to the patient and their doctor.
study drupee Pavel Hamet, Johanne Tremblay and their team of researchers have been published in the scientific journal diabetes, Official GazetteEuropean Association for the Study of Diabetes [EASD]). He notes that nearly 600 genetic variants associated with cardiovascular disease and kidney disease were selected from more than one million individuals. The team also analyzed clinical and genetic data from participants from 17 countries in the ADVANCE Study, a large global clinical study on people with diabetes. In addition, the test was They were validated in four independent groups, including the largest UK database.
More studies need to be done to see if the test also works for juvenile diabetes.